{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:55:24Z","timestamp":1793692524575,"version":"4.5.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22437005"],"award-info":[{"award-number":["22437005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Difelikefalin is an FDA-approved \u03ba-opioid receptor (KOR) peptide agonist used to treat chronic pruritus. However, as a balanced agonist that activates both G protein and \u03b2-arrestin pathways, difelikefalin remains associated with undesirable side effects linked to \u03b2-arrestin signaling. Here, we report the cryo-EM structure of the difelikefalin-KOR-Gi complex, identifying Y320\n                    <jats:sup>7.43<\/jats:sup>\n                    as a key residue that is critical for signaling bias. Guided by this structural insight, we engineer beta01, a \u03b2-amino acid-substituted analog with potent G protein activation but minimal \u03b2-arrestin recruitment. In mouse models, beta01 retains robust antinociceptive and antipruritic efficacy while significantly reducing sedation and anxiety-like behaviors. Structural, molecular dynamics simulations and 2D\n                    <jats:sup>13<\/jats:sup>\n                    C-Met NMR analyses further reveal beta01 stabilizes a unique KOR conformation with an expanded intracellular cavity that disfavors \u03b2-arrestin binding. This work establishes a rational structure-based framework for designing safer and more effective GPCR-targeted therapeutics.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-71455-3","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:55:08Z","timestamp":1776178508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Rational design of a Kappa opioid receptor peptide agonist with attenuated \u03b2-arrestin signaling"],"prefix":"10.1038","volume":"17","author":[{"given":"Huanhuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1538-3503","authenticated-orcid":false,"given":"Ruolan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7813-5480","authenticated-orcid":false,"given":"Xinheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8069-7511","authenticated-orcid":false,"given":"Youwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingning","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-0185","authenticated-orcid":false,"given":"Yingbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1380-8047","authenticated-orcid":false,"given":"Youwen","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-8144","authenticated-orcid":false,"given":"H. Eric","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3716-2922","authenticated-orcid":false,"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9315-900X","authenticated-orcid":false,"given":"Changlin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"71455_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1146\/annurev-med-062613-093100","volume":"67","author":"C Stein","year":"2016","unstructured":"Stein, C. Opioid Receptors. Annu Rev. Med 67, 433\u2013451 (2016).","journal-title":"Annu Rev. Med"},{"key":"71455_CR2","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1016\/j.cell.2023.10.029","volume":"186","author":"T Che","year":"2023","unstructured":"Che, T. & Roth, B. L. Molecular basis of opioid receptor signaling. Cell 186, 5203\u20135219 (2023).","journal-title":"Cell"},{"key":"71455_CR3","first-page":"1091","volume":"14","author":"AK Paul","year":"2021","unstructured":"Paul, A. K. et al. Opioid Analgesia and Opioid-Induced Adverse Effects: A Review. Pharm. (Basel) 14, 1091\u20131110 (2021).","journal-title":"Pharm. (Basel)"},{"key":"71455_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/SPC.0000000000000495","volume":"14","author":"C Stein","year":"2020","unstructured":"Stein, C. Opioid analgesia: recent developments. Curr. Opin. Support Palliat. Care 14, 112\u2013117 (2020).","journal-title":"Curr. Opin. Support Palliat. Care"},{"key":"71455_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14728222.2019.1586882","volume":"23","author":"AT Ehrlich","year":"2019","unstructured":"Ehrlich, A. T., Kieffer, B. L. & Darcq, E. Current strategies toward safer mu opioid receptor drugs for pain management. Expert Opin. Ther. Targets 23, 315\u2013326 (2019).","journal-title":"Expert Opin. Ther. Targets"},{"key":"71455_CR6","doi-asserted-by":"publisher","first-page":"837671","DOI":"10.3389\/fphar.2022.837671","volume":"13","author":"ML Dalefield","year":"2022","unstructured":"Dalefield, M. L., Scouller, B., Bibi, R. & Kivell, B. M. The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies. Front Pharm. 13, 837671 (2022).","journal-title":"Front Pharm."},{"key":"71455_CR7","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1213\/ANE.0000000000005309","volume":"132","author":"SW Kaski","year":"2021","unstructured":"Kaski, S. W., White, A. N., Gross, J. D. & Siderovski, D. P. Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review. Anesth. Analg. 132, 406\u2013419 (2021).","journal-title":"Anesth. Analg."},{"key":"71455_CR8","first-page":"95","volume":"12","author":"TC Beck","year":"2019","unstructured":"Beck, T. C., Hapstack, M. A., Beck, K. R. & Dix, T. A. Therapeutic Potential of Kappa Opioid Agonists. Pharm. (Basel) 12, 95 (2019).","journal-title":"Pharm. (Basel)"},{"key":"71455_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/npp.2010.137","volume":"36","author":"C Chavkin","year":"2011","unstructured":"Chavkin, C. The therapeutic potential of kappa-opioids for treatment of pain and addiction. Neuropsychopharmacology 36, 369\u2013370 (2011).","journal-title":"Neuropsychopharmacology"},{"key":"71455_CR10","first-page":"e0072","volume":"8","author":"TC Beck","year":"2023","unstructured":"Beck, T. C. et al. Kappa opioid agonists in the treatment of itch: just scratching the surface?. Itch (Philos.) 8, e0072 (2023).","journal-title":"Itch (Philos.)"},{"key":"71455_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3892\/mmr.2021.12560","volume":"25","author":"Q Zhou","year":"2022","unstructured":"Zhou, Q. et al. Opioids in cancer: The kappa\u2011opioid receptor (Review). Mol. Med Rep. 25, 44 (2022).","journal-title":"Mol. Med Rep."},{"key":"71455_CR12","doi-asserted-by":"publisher","first-page":"856672","DOI":"10.3389\/fphar.2022.856672","volume":"13","author":"C Leconte","year":"2022","unstructured":"Leconte, C., Mongeau, R. & Noble, F. Traumatic Stress-Induced Vulnerability to Addiction: Critical Role of the Dynorphin\/Kappa Opioid Receptor System. Front Pharm. 13, 856672 (2022).","journal-title":"Front Pharm."},{"key":"71455_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1146\/annurev-pharmtox-052120-091058","volume":"63","author":"E Kelly","year":"2023","unstructured":"Kelly, E., Conibear, A. & Henderson, G. Biased Agonism: Lessons from Studies of Opioid Receptor Agonists. Annu Rev. Pharm. Toxicol. 63, 491\u2013515 (2023).","journal-title":"Annu Rev. Pharm. Toxicol."},{"key":"71455_CR14","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.3390\/ijms23095114","volume":"23","author":"A Bedini","year":"2022","unstructured":"Bedini, A., Cuna, E., Baiula, M. & Spampinato, S. Quantitative Systems Pharmacology and Biased Agonism at Opioid Receptors: A Potential Avenue for Improved Analgesics. Int J. Mol. Sci. 23, 5114\u20135131 (2022).","journal-title":"Int J. Mol. Sci."},{"key":"71455_CR15","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/35047086","volume":"408","author":"LM Bohn","year":"2000","unstructured":"Bohn, L. M., Gainetdinov, R. R., Lin, F.-T., Lefkowitz, R. J. & Caron, M. G. \u03bc-Opioid receptor desensitization by \u03b2-arrestin\u22122 determines morphine tolerance but not dependence. Lett. Nat. 408, 720\u2013723 (2000).","journal-title":"Lett. Nat."},{"key":"71455_CR16","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","volume":"286","author":"LauraM Bohn","year":"1999","unstructured":"Bohn, L. auraM. et al. Enhanced Morphine Analgesia in Mice Lacking P-Arrestin 2. Science 286, 2495\u20132498 (1999).","journal-title":"Science"},{"key":"71455_CR17","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1124\/jpet.105.087254","volume":"314","author":"KM Raehal","year":"2005","unstructured":"Raehal, K. M., Walker, J. K. & Bohn, L. M. Morphine side effects in beta-arrestin 2 knockout mice. J. Pharm. Exp. Ther. 314, 1195\u20131201 (2005).","journal-title":"J. Pharm. Exp. Ther."},{"key":"71455_CR18","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1111\/bph.15004","volume":"177","author":"A Kliewer","year":"2020","unstructured":"Kliewer, A. et al. Morphine-induced respiratory depression is independent of beta-arrestin2 signalling. Br. J. Pharm. 177, 2923\u20132931 (2020).","journal-title":"Br. J. Pharm."},{"key":"71455_CR19","doi-asserted-by":"publisher","first-page":"106961","DOI":"10.1016\/j.phrs.2023.106961","volume":"197","author":"N Ramos-Gonzalez","year":"2023","unstructured":"Ramos-Gonzalez, N., Paul, B. & Majumdar, S. IUPHAR themed review: Opioid efficacy, bias, and selectivity. Pharm. Res. 197, 106961 (2023).","journal-title":"Pharm. Res."},{"key":"71455_CR20","doi-asserted-by":"publisher","first-page":"106091","DOI":"10.1016\/j.phrs.2022.106091","volume":"177","author":"AR French","year":"2022","unstructured":"French, A. R. & van Rijn, R. M. An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects. Pharm. Res. 177, 106091 (2022).","journal-title":"Pharm. Res."},{"key":"71455_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fphar.2019.00407","volume":"10","author":"KL Mores","year":"2019","unstructured":"Mores, K. L., Cummins, B. R., Cassell, R. J. & van Rijn, R. M. A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists. Front Pharm. 10, 407\u2013420 (2019).","journal-title":"Front Pharm."},{"key":"71455_CR22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.neuropharm.2015.08.027","volume":"99","author":"J Morgenweck","year":"2015","unstructured":"Morgenweck, J., Frankowski, K. J., Prisinzano, T. E., Aube, J. & Bohn, L. M. Investigation of the role of betaarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus. Neuropharmacology 99, 600\u2013609 (2015).","journal-title":"Neuropharmacology"},{"key":"71455_CR23","doi-asserted-by":"publisher","first-page":"114785","DOI":"10.1016\/j.ejmech.2022.114785","volume":"243","author":"MIH Khan","year":"2022","unstructured":"Khan, M. I. H., Sawyer, B. J., Akins, N. S. & Le, H. V. A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse. Eur. J. Med Chem. 243, 114785 (2022).","journal-title":"Eur. J. Med Chem."},{"key":"71455_CR24","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.3390\/molecules25184257","volume":"25","author":"A Faouzi","year":"2020","unstructured":"Faouzi, A., Varga, B. R. & Majumdar, S. Biased Opioid Ligands. Molecules 25, 4257 (2020).","journal-title":"Molecules"},{"key":"71455_CR25","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1111\/bph.13854","volume":"174","author":"M Spetea","year":"2017","unstructured":"Spetea, M. et al. Selective kappa receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice. Br. J. Pharm. 174, 2444\u20132456 (2017).","journal-title":"Br. J. Pharm."},{"key":"71455_CR26","doi-asserted-by":"publisher","first-page":"ra117","DOI":"10.1126\/scisignal.aai8441","volume":"9","author":"TF Brust","year":"2016","unstructured":"Brust, T. F. et al. Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci. Signal. 9, ra117 (2016).","journal-title":"Sci. Signal."},{"key":"71455_CR27","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1021\/acsmedchemlett.7b00224","volume":"8","author":"LM Bohn","year":"2017","unstructured":"Bohn, L. M. & Aube, J. Seeking (and Finding) Biased Ligands of the Kappa Opioid Receptor. ACS Med Chem. Lett. 8, 694\u2013700 (2017).","journal-title":"ACS Med Chem. Lett."},{"key":"71455_CR28","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1021\/acsmedchemlett.0c00287","volume":"11","author":"X Li","year":"2020","unstructured":"Li, X. et al. Discovery of SHR0687, a Highly Potent and Peripheral Nervous System-Restricted KOR Agonist. ACS Med Chem. Lett. 11, 2151\u20132155 (2020).","journal-title":"ACS Med Chem. Lett."},{"key":"71455_CR29","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/17512433.2023.2197209","volume":"16","author":"A Rastogi","year":"2023","unstructured":"Rastogi, A., Fishbane, S. & Lerma, E. Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis. Expert Rev. Clin. Pharm. 16, 384\u2013400 (2023).","journal-title":"Expert Rev. Clin. Pharm."},{"key":"71455_CR30","first-page":"934","volume":"15","author":"K Wala","year":"2022","unstructured":"Wala, K. & Szepietowski, J. C. Difelikefalin in the Treatment of Chronic Kidney Disease-Associated Pruritus: A Systematic Review. Pharm. (Basel) 15, 934\u2013949 (2022).","journal-title":"Pharm. (Basel)"},{"key":"71455_CR31","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2023.06.022","volume":"152","author":"M Tamari","year":"2023","unstructured":"Tamari, M. et al. Difelikefalin suppresses itch and reduces scratching independent of inflammation in a murine model of atopic dermatitis. J. Allergy Clin. Immunol. 152, 927\u2013932 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"71455_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jcpt.12404","volume":"41","author":"A Albert-Vartanian","year":"2016","unstructured":"Albert-Vartanian, A. et al. Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?. J. Clin. Pharm. Ther. 41, 371\u2013382 (2016).","journal-title":"J. Clin. Pharm. Ther."},{"key":"71455_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/1744666X.2023.2272048","volume":"20","author":"RH Mahmoud","year":"2024","unstructured":"Mahmoud, R. H., Mahmoud, O. & Yosipovitch, G. Intravenous difelikefalin for the treatment of hemodialysis pruritus. Expert Rev. Clin. Immunol. 20, 31\u201337 (2024).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"71455_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.110157","volume":"261","author":"Kangtai Xu","year":"2024","unstructured":"Xu, K. angtai et al. Conorphin-66 produces peripherally restricted antinociception via the kappa-opioid receptor with limited side effects. Neuropharmacology 261, 110157 (2024).","journal-title":"Neuropharmacology"},{"key":"71455_CR35","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/s41401-021-00761-x","volume":"43","author":"YY Wei","year":"2022","unstructured":"Wei, Y. Y. et al. Novel selective kappa agonists SLL-039 and SLL\u22121206 produce potent antinociception with fewer sedation and aversion. Acta Pharm. Sin. 43, 1372\u20131382 (2022).","journal-title":"Acta Pharm. Sin."},{"key":"71455_CR36","doi-asserted-by":"publisher","first-page":"10377","DOI":"10.1021\/acs.jmedchem.2c00014","volume":"65","author":"L Kong","year":"2022","unstructured":"Kong, L. et al. SLL-627 Is a Highly Selective and Potent kappa Opioid Receptor (KOR) Agonist with an Unexpected Nonreduction in Locomotor Activity. J. Med Chem. 65, 10377\u201310392 (2022).","journal-title":"J. Med Chem."},{"key":"71455_CR37","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/aps.2014.145","volume":"36","author":"LS Zhang","year":"2015","unstructured":"Zhang, L. S. et al. Novel kappa-opioid receptor agonist MB-1C-OH produces potent analgesia with less depression and sedation. Acta Pharm. Sin. 36, 565\u2013571 (2015).","journal-title":"Acta Pharm. Sin."},{"key":"71455_CR38","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jpain.2019.08.016","volume":"21","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. Spinal DN-9, a Peptidic Multifunctional Opioid\/Neuropeptide FF Agonist Produced Potent Nontolerance Forming Analgesia With Limited Side Effects. J. Pain. 21, 477\u2013493 (2020).","journal-title":"J. Pain."},{"key":"71455_CR39","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.cell.2018.12.005","volume":"176","author":"LM Wingler","year":"2019","unstructured":"Wingler, L. M. et al. Angiotensin Analogs with Divergent Bias Stabilize Distinct Receptor Conformations. Cell 176, 468\u2013478 e411 (2019).","journal-title":"Cell"},{"key":"71455_CR40","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41586-020-2419-1","volume":"583","author":"Y Lee","year":"2020","unstructured":"Lee, Y. et al. Molecular basis of beta-arrestin coupling to formoterol-bound beta1-adrenoceptor. Nature 583, 862\u2013866 (2020).","journal-title":"Nature"},{"key":"71455_CR41","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1016\/j.cell.2022.09.041","volume":"185","author":"Y Zhuang","year":"2022","unstructured":"Zhuang, Y. et al. Molecular recognition of morphine and fentanyl by the human \u03bc-opioid receptor. Cell 185, 4361\u20134375.e4319 (2022).","journal-title":"Cell"},{"key":"71455_CR42","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41422-025-01095-7","volume":"35","author":"D Sun","year":"2025","unstructured":"Sun, D. et al. Molecular mechanism of the arrestin-biased agonism of neurotensin receptor 1 by an intracellular allosteric modulator. Cell Res. 35, 284\u2013295 (2025).","journal-title":"Cell Res."},{"key":"71455_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38894-8","volume":"14","author":"F Bumbak","year":"2023","unstructured":"Bumbak, F. et al. Stabilization of pre-existing neurotensin receptor conformational states by beta-arrestin\u22121 and the biased allosteric modulator ML314. Nat. Commun. 14, 3328 (2023).","journal-title":"Nat. Commun."},{"key":"71455_CR44","doi-asserted-by":"crossref","unstructured":"Kaneko, S. et al. Activation mechanism of the \u03bc-opioid receptor by an allosteric modulator. Proc. Natl. Acad. Sci. 119, e2121918119 (2022).","DOI":"10.1073\/pnas.2121918119"},{"key":"71455_CR45","doi-asserted-by":"publisher","first-page":"15771","DOI":"10.1002\/anie.201508794","volume":"54","author":"J Okude","year":"2015","unstructured":"Okude, J. et al. Identification of a Conformational Equilibrium That Determines the Efficacy and Functional Selectivity of the mu-Opioid Receptor. Angew. Chem. Int Ed. Engl. 54, 15771\u201315776 (2015).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"71455_CR46","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.str.2012.04.010","volume":"20","author":"E Chun","year":"2012","unstructured":"Chun, E. et al. Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure 20, 967\u2013976 (2012).","journal-title":"Structure"},{"key":"71455_CR47","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1038\/aps.2016.69","volume":"37","author":"P Liu","year":"2016","unstructured":"Liu, P. et al. The structural basis of the dominant negative phenotype of the G\u03b1i1\u03b21\u03b32 G203A\/A326S heterotrimer. Acta Pharm. Sin. 37, 1259\u20131272 (2016).","journal-title":"Acta Pharm. Sin."},{"key":"71455_CR48","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1038\/s41467-020-17933-8","volume":"11","author":"J Duan","year":"2020","unstructured":"Duan, J. et al. Cryo-EM structure of an activated VIP1 receptor-G protein complex revealed by a NanoBiT tethering strategy. Nat. Commun. 11, 4121\u20134130 (2020).","journal-title":"Nat. Commun."},{"key":"71455_CR49","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1038\/s41467-018-06002-w","volume":"9","author":"S Maeda","year":"2018","unstructured":"Maeda, S. et al. Development of an antibody fragment that stabilizes GPCR\/G-protein complexes. Nat. Commun. 9, 3712\u20133720 (2018).","journal-title":"Nat. Commun."},{"key":"71455_CR50","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nmeth.4193","volume":"14","author":"SQ Zheng","year":"2017","unstructured":"Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331\u2013332 (2017).","journal-title":"Nat. Methods"},{"key":"71455_CR51","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jsb.2015.08.008","volume":"192","author":"A Rohou","year":"2015","unstructured":"Rohou, A. & Grigorieff, N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 192, 216\u2013221 (2015).","journal-title":"J. Struct. Biol."},{"key":"71455_CR52","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2013a visualization system for exploratory research and analysis. J. Comput Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput Chem."},{"key":"71455_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14728-9","volume":"11","author":"Y Zhuang","year":"2020","unstructured":"Zhuang, Y. et al. Structure of formylpeptide receptor 2-Gi complex reveals insights into ligand recognition and signaling. Nat. Commun. 11, 885 (2020).","journal-title":"Nat. Commun."},{"key":"71455_CR54","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D. Biol. Crystallogr 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"71455_CR55","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."},{"key":"71455_CR56","doi-asserted-by":"publisher","first-page":"7112","DOI":"10.1021\/acs.jmedchem.3c02439","volume":"67","author":"Z Li","year":"2024","unstructured":"Li, Z. et al. Discovery of an Ortho-Substituted N-Cyclopropylmethyl-7alpha-phenyl-6,14-endoethano-tetrahydronorthebaine Derivative as a Selective and Potent Kappa Opioid Receptor Agonist with Subsided Sedative Effect. J. Med Chem. 67, 7112\u20137129 (2024).","journal-title":"J. Med Chem."},{"key":"71455_CR57","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00210-022-02317-0","volume":"396","author":"A Hajizadeh Moghaddam","year":"2023","unstructured":"Hajizadeh Moghaddam, A., Mashayekhpour, M. A. & Tabari, M. A. Anxiolytic-like effects of citral in the mouse elevated plus maze: involvement of GABAergic and serotonergic transmissions. Naunyn Schmiedebergs Arch. Pharm. 396, 301\u2013309 (2023).","journal-title":"Naunyn Schmiedebergs Arch. Pharm."},{"key":"71455_CR58","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.phymed.2012.09.015","volume":"20","author":"L Ma","year":"2012","unstructured":"Ma, L. et al. Effects of bilobalide on anxiety, spatial learning, memory and levels of hippocampal glucocorticoid receptors in male Kunming mice. Phytomedicine 20, 89\u201396 (2012).","journal-title":"Phytomedicine"},{"key":"71455_CR59","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/NDT.S151107","volume":"14","author":"J Zhao","year":"2018","unstructured":"Zhao, J. et al. The depressive-like behaviors of chronic unpredictable mild stress-treated mice, ameliorated by Tibetan medicine Zuotai: involvement in the hypothalamic-pituitary-adrenal (HPA) axis pathway. Neuropsychiatr. Dis. Treat. 14, 129\u2013141 (2018).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"71455_CR60","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1021\/acs.jcim.9b00269","volume":"59","author":"S Schott-Verdugo","year":"2019","unstructured":"Schott-Verdugo, S. & Gohlke, H. PACKMOL-Memgen: A Simple-To-Use, Generalized Workflow for Membrane-Protein\u2013Lipid-Bilayer System Building. J. Chem. Inf. Modeling 59, 2522\u20132528 (2019).","journal-title":"J. Chem. Inf. Modeling"},{"key":"71455_CR61","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1021\/ct200133y","volume":"7","author":"CR Sondergaard","year":"2011","unstructured":"Sondergaard, C. R., Olsson, M. H., Rostkowski, M. & Jensen, J. H. Improved Treatment of Ligands and Coupling Effects in Empirical Calculation and Rationalization of pKa Values. J. Chem. Theory Comput. 7, 2284\u20132295 (2011).","journal-title":"J. Chem. Theory Comput."},{"key":"71455_CR62","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1021\/acs.jctc.9b00591","volume":"16","author":"C Tian","year":"2020","unstructured":"Tian, C. et al. ff19SB: Amino-Acid-Specific Protein Backbone Parameters Trained against Quantum Mechanics Energy Surfaces in Solution. J. Chem. Theory Comput. 16, 528\u2013552 (2020).","journal-title":"J. Chem. Theory Comput."},{"key":"71455_CR63","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1021\/acs.jctc.1c01217","volume":"18","author":"CJ Dickson","year":"2022","unstructured":"Dickson, C. J., Walker, R. C. & Gould, I. R. Lipid21: Complex Lipid Membrane Simulations with AMBER. J. Chem. Theory Comput. 18, 1726\u20131736 (2022).","journal-title":"J. Chem. Theory Comput."},{"key":"71455_CR64","doi-asserted-by":"publisher","first-page":"114502","DOI":"10.1063\/5.0019056","volume":"153","author":"X He","year":"2020","unstructured":"He, X., Man, V. H., Yang, W., Lee, T. S. & Wang, J. A fast and high-quality charge model for the next generation general AMBER force field. J. Chem. Phys. 153, 114502 (2020).","journal-title":"J. Chem. Phys."},{"key":"71455_CR65","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3390\/molecules26040962","volume":"26","author":"X He","year":"2021","unstructured":"He, X. et al. Conformational Selection Mechanism Provides Structural Insights into the Optimization of APC-Asef Inhibitors. Molecules 26, 962 (2021).","journal-title":"Molecules"},{"key":"71455_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25020-9","volume":"12","author":"S Lu","year":"2021","unstructured":"Lu, S. et al. Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design. Nat. Commun. 12, 4721 (2021).","journal-title":"Nat. Commun."},{"key":"71455_CR67","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1021\/ct400314y","volume":"9","author":"R Salomon-Ferrer","year":"2013","unstructured":"Salomon-Ferrer, R. et al. Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. J. Chem. Theory Comput. 9, 3878\u20133888 (2013).","journal-title":"J. Chem. Theory Comput."},{"key":"71455_CR68","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1021\/acs.jctc.9b00160","volume":"15","author":"C Balusek","year":"2019","unstructured":"Balusek, C. et al. Accelerating Membrane Simulations with Hydrogen Mass Repartitioning. J. Chem. Theory Comput. 15, 4673\u20134686 (2019).","journal-title":"J. Chem. Theory Comput."},{"key":"71455_CR69","doi-asserted-by":"publisher","first-page":"015102","DOI":"10.1063\/1.4811489","volume":"139","author":"G Perez-Hernandez","year":"2013","unstructured":"Perez-Hernandez, G., Paul, F., Giorgino, T., De Fabritiis, G. & Noe, F. Identification of slow molecular order parameters for Markov model construction. J. Chem. Phys. 139, 015102 (2013).","journal-title":"J. Chem. Phys."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71455-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71455-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71455-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:02:54Z","timestamp":1781827374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71455-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71455"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71455-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.E.X is a founder of Cascade Pharmaceutics. C.T. is a founder of Hefei KS-V Peptide Biological Technology Co. Ltd.; All the other authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5439"}}